Clinical Trial Update: ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B [Phase 3]

View source ↗

Summary

The ADVANCE Phase 3 trial evaluating PEGASYS (peginterferon alfa-2a) plus adefovir dipivoxil in patients with HBeAg-negative chronic hepatitis B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Hepsera (adefovir dipivoxil)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis B, Chronic | Phase 3 | Status: COMPLETED